Document:

Amendment No. 4 to Development and License Agreement between Glaxo Group Limited

 Exhibit 10.1 
 Portions of this exhibit marked [ * ] are omitted and requested to be treated confidentially. 
 AMENDMENT
NO. 4 
 to 
 DEVELOPMENT AND LICENSE AGREEMENT 
 between 
 GLAXO GROUP LIMITED 
 and 
 ADHEREX TECHNOLOGIES INC. 
 THIS AMENDMENT NO. 4 (this “Fourth Amendment”) effective on this 23rd day of May, 2007 (the “Fourth Amendment Effective Date”), is entered into by and between Glaxo Group Limited,
a company organized under the laws of England and Wales, having its registered office at GlaxoWellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN United Kingdom (“GGL”) and Adherex Technologies Inc., a company organized
under the laws of Canada and having an office located at 4620 Creekstone Drive, Suite 200, Durham, North Carolina, 27703 USA (“Adherex”): 
 RECITALS 
 A. The Parties entered into the Development and License Agreement, effective as of July 14, 2005 (the
“Agreement”). 
 B. The Parties entered into Amendment No. 1 to the Agreement, effective December 20, 2005, relating to the ExherinTM
Option. 
 C. The Parties entered into Amendment No. 2 to the Agreement, effective June 23, 2006, relating to Eniluracil. 
 D. The Parties entered into Amendment No. 3 to the Agreement, effective January 16, 2007, relating to the expiration of the GGL Options. 
 E. The Parties now desire to further amend the Agreement on the terms and conditions set forth below. 
 NOW THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties, intending to be legally bound, hereby amend the Agreement and otherwise agree as follows: 
 1. Defined Terms. All terms used in this Fourth Amendment but not defined herein shall have the same meaning as set forth in the Agreement. 
 2. Amendment to Section 13.2 Section 13.2 is hereby amended and restated in its entirety to read as follows: 
 “13.2 Royalties to Adherex on Exercise or Expiration of GGL Option. If GGL exercises any of the GGL Options, GGL will pay Adherex the
following percentages of any royalties that GGL receives from [ * ] on Net Sales by [ * ] of Product in the [ * ] Territory: 
 (a) If GGL
exercises Option B, GGL will pay Adherex [ * ] percent ([ * ]%) of any royalties received by GGL from [ * ]; 
  
 [ * ] Confidential treatment requested; certain information omitted and filed separately with the SEC 
  

 1 

 (b) If GGL exercises Option C, GGL will pay Adherex [ * ] percent ([ * ]%) of any royalties received by
GGL from [ * ]; and 
 (c) If GGL exercises Option E, GGL will pay Adherex [ * ] percent ([ * ]%) of any royalties received by GGL from [ * ].

 If all GGL Options expire, and unless and until the [ * ] License is assigned to Adherex, beginning on the date of the last to expire GGL
Option, GGL will pay Adherex [ * ] percent ([ * ]%) of any royalties received by GGL from [ * ] under the [ * ] License.” 
 3. Amendment to
Section 13.3. Section 13.3 is hereby amended and restated in its entirety to read as follows: 
 “13.3 Sharing of Data
with [ * ]. GGL shall have the right to share with [ * ], without the prior written consent of Adherex, any data and Adherex Know How received from Adherex regarding Eniluracil or Products to assist [ * ] in its Development and Commercialization
of Eniluracil and Products in the [ * ] Territory. Unless and until GGL exercises one of the GGL Options, if and as specifically requested by Adherex, GGL shall promptly provide to Adherex any data and information received from [ * ] regarding
Eniluracil or Products to assist Adherex in its Development and Commercialization of Eniluracil and Products in the Territory to the extent GGL may do so pursuant to the terms of the applicable [ * ] Agreements and, to the extent GGL may do so
pursuant to the terms of the applicable [ * ] Agreements, GGL hereby grants Adherex a right of reference for regulatory approval purposes with respect to such data and information. Upon expiration of all of the GGL Options, and continuing for
the remainder of the Term unless and until the [ * ] Agreements are assigned to Adherex, if and as specifically requested by GGL, Adherex shall promptly provide GGL with all Adherex Know How and GGL shall have the right to share with [ * ] under
conditions of confidentiality substantially equivalent to those established under Section 9 hereof, without the prior written consent of Adherex, any data and Adherex Know How received from Adherex regarding Eniluracil or Products to assist [ *
] in its Development and Commercialization of Eniluracil and Products in the [ * ] Territory.” 
 4. Amendment of Section 15.4.1(b)(2).
Section 15.4.1(b)(2) is hereby amended and restated in the entirety to read as follows: 
 “(2) Termination by
GGL for Material Breach at Any Time After Expiration of GGL Option B and GGL Option E and Prior to the Expiration of All GGL Options: 
 (i) All licenses granted by Adherex to GGL or its Affiliates under this Agreement prior to termination will survive, subject to GGL’s continued obligation to pay milestones and royalties to Adherex hereunder if
GGL continues the Development and Commercialization of Eniluracil or a Product consistent with Sections 8.1.2 (Option C), 8.2.1, 8.4, 8.5.3, 12.2, and 13.2, subject to any adjustments to such amounts consistent with Sections 8.6 through 8.10;

  
 [ * ] Confidential treatment requested; certain information omitted and filed
separately with the SEC 
  

 2 

 (ii) All licenses granted by GGL to Adherex under this Agreement will terminate;

 (iii) GGL shall have the right to continue Development and Commercialization of Eniluracil or a Product, by itself or its
Affiliates or through a Third Party, provided, 
 (I) if, at the time of such termination, GGL does not have any licenses
from Adherex, GGL shall become the Licensee by virtue of such termination, and 
 (II) GGL shall be obligated to pay
milestones, royalties, portions of any amounts recovered from Third Parties in settlement or as recovery for infringement, and a portion of any amounts received under the [ * ] Agreements to Adherex hereunder if GGL continues the Development and
Commercialization of Eniluracil or a Product consistent with Sections 8.1.2 (Option C), 8.2.1, 8.4, 8.5.3, 12.2, and 13.2, subject to any adjustments to such amounts consistent with Sections 8.6 through 8.10; 
 (iv) GGL will retain all of its rights to bring an action against Adherex for damages and any other available remedies in law or equity
and will be entitled to set-off against any monies payable to Adherex hereunder against all amounts GGL reasonably believes constitute its damages incurred by such breach, subject to final judicial resolution or settlement; 
 Adherex, at its sole expense, will promptly transfer to GGL, or will cause its designee(s) to transfer to GGL, ownership of all regulatory filings,
approvals, correspondence, all Trial information and data, and conversation logs made or filed for each Product (to the extent that any are held in Adherex’s or such designee(s)’s name) and information and data set forth in Appendix 7, to
the extent not previously transferred to GGL (collectively, “Adherex Filings”), such transfer to be as permitted by applicable Laws, and Adherex will otherwise fully cooperate to permit GGL to fully exercise its rights hereunder; and

  
 [ * ] Confidential treatment requested; certain information omitted and filed
separately with the SEC 
  

 3 

 (v) Adherex, at its sole expense, promptly shall return to GGL, or destroy at GGL’s
request, all relevant records and materials in its possession or control containing Confidential Information of GGL; provided, however, that Adherex may keep one copy of such Confidential Information for archival purposes only in accordance with
Section 10.5.”. 
 5. Addition of Section 15.4.1(b)(3). Section 15.4.1(b)(3) is hereby added to the Agreement to read in the
entirety as follows: 
 “(3) Termination by GGL for Material Breach at Any Time After Expiration of all GGL Options: 

(i) All licenses granted by GGL to Adherex under this Agreement will terminate; 
 (ii) GGL shall have the right, in the absence of any Valid Claims of any Adherex Patents which would be infringed by, or the use of any
Adherex Know-How which is not in the public domain in, the Development or Commercialization of Eniluracil or a Product, to continue Development and Commercialization of Eniluracil or a Product, by itself or its Affiliates or through a Third Party,
provided, 
 (I) GGL shall not by virtue of such termination have or be granted any licenses from Adherex; and 
 (II) GGL shall not be obligated to pay any milestones or royalties to Adherex hereunder if, in the absence of any Valid Claims of any Adherex Patents
which would be infringed by, or the use of any Adherex Know-How which is not in the public domain in, the Development or Commercialization of Eniluracil or a Product, GGL continues the Development and Commercialization of Eniluracil or a Product
other than royalties pursuant to Section 8.5.3, which shall be payable to Adherex based on any Net Sales of any Product enjoying Regulatory Exclusivity due to an Orphan Drug Designation or similar designation or equivalent obtained by Adherex
in the Territory; 
 (ii) GGL will retain all of its rights to bring an action against Adherex for damages and any other
available remedies in law or equity and will be entitled to set-off against any monies payable to Adherex hereunder against all amounts GGL reasonably believes constitute its damages incurred by such breach, subject to final judicial resolution or
settlement; and 
 (vi) Adherex, at its sole expense, promptly shall return to GGL, or destroy at GGL’s request, all
relevant records and materials in its possession or control containing Confidential Information of GGL; provided, however, that Adherex may keep one copy of such Confidential Information for archival purposes only in accordance with
Section 10.5.” 
  
 [ * ] Confidential treatment requested; certain
information omitted and filed separately with the SEC 
  

 4 

 6. Amendment of Section 15.5. Section 15.5 is hereby amended and restated in its entirety to read as
follows: 
 15.5 Accrued Rights; Surviving Obligations. Except as provided elsewhere, termination or expiration of this Agreement for
any reason will be without prejudice to any rights that will have accrued to the benefit of any Party prior to such termination or expiration. Such termination or expiration will not relieve any Party from obligations which are expressly or by
implication intended to survive termination or expiration of this Agreement, including but not limited to, definitions, rights to payment, and Sections 7.5, 8.12, 8.13, 8.14, 8.15, 8.16, 8.17 (for the period stated therein), 9, 10, 11, 12.2 (with
respect to actual or alleged infringement occurring prior to such termination or expiration), 12.3, 12.4, 12.5, 15.1, 15.2, 15.3, 15.4, and 16 and will not affect or prejudice any provision of this Agreement which is expressly or by implication
provided to come into effect on, or continue in effect after, such termination or expiration. The following additional sections will also survive in the event of termination for material breach: (a) by GGL under Section 15.4.1(a), Sections
4.1, 4.3.1, 7.5.1, 7.8.3, 8.1.1, 8.2.2, 8.2.3, 8.3, 8.5, 8.6, 8.7, 8.8, 8.9, 8.10, 8.11, 12.1, 12.2, 13.1.1, 13.2 and 13.3; (b) by Adherex under Section 15.4.1(b)(1), Section 8.5.3; (c) by Adherex under Section 15.4.1(b)(2),
Sections 4.2, 8.1.2 (Option C), 8.2.1, 8.2.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 8.10, and 13.2; and (d) by Adherex under Section 15.4.1(b)(3), Section 8.5.3. 
 7. Binding Effect. This Fourth Amendment shall be binding upon and inure to the benefit of the Parties hereto, their permitted successors, legal representatives and assigns. 
 8. Waiver. No waiver of any term or condition of this Fourth Amendment will be effective unless set forth in a written instrument that explicitly refers to
this Fourth Amendment that is duly executed by or on behalf of the waiving Party. No waiver by any Party of any term or condition of this Fourth Amendment, in any one or more instances, will be deemed to be or construed as a waiver of the same or
any other term or condition of this Fourth Amendment on any prior, concurrent or future occasion. Except as expressly set forth in this Fourth Amendment, all rights and remedies available to a Party, whether under this Fourth Amendment or afforded
by Law or otherwise, will be cumulative and not in the alternative to any other rights or remedies that may be available to such Party. 
 9.
Severability. If any provision of this Fourth Amendment is held to be invalid, illegal or unenforceable in any respect, that provision will be limited or eliminated to the minimum extent necessary so that this Fourth Amendment will otherwise
remain in full force and effect and enforceable. 
  
 [ * ] Confidential treatment
requested; certain information omitted and filed separately with the SEC 
  

 5 

 10. Governing Law. This Fourth Amendment will be construed, and the respective rights of the Parties determined,
according to the substantive law of the State of North Carolina without regard to the provisions governing conflict of laws. 
 11. Counterparts. This
Fourth Amendment may be executed in any two counterparts, each of which, when executed, will be deemed to be an original and both of which together will constitute one and the same document. 
 12. Continuing Effect. All other terms and conditions of the Agreement shall remain in full force and effect. 
 [Remainder of page intentionally left blank. Signature page follows.] 
  
 [ * ] Confidential treatment requested; certain information omitted and filed separately with the SEC 
  

 6 

 IN WITNESS WHEREOF, Glaxo Group Limited and Adherex Technologies Inc., by their duly authorized representatives, have
executed this Amendment No. 4 as of the Fourth Amendment Effective Date. 
  

							
	GLAXO GROUP LIMITED	 	ADHEREX TECHNOLOGIES INC.
				
	By:	 	 /s/ Paul Williamson
	 	By:	 	 /s/ D. Scott Murray

	Name:	 	Paul Williamson	 	Name:	 	D. Scott Murray
		 	For and on behalf of	 		 	
		 	Edinburgh Pharmaceutical Industries Ltd	 		 	
	Title:	 	Corporate Director	 	Title:	 	SVP, General Counsel

  
 [ * ] Confidential treatment
requested; certain information omitted and filed separately with the SEC 
  

 7Form of Common Stock Purchase Warrant

 Exhibit 10.1 
 THE WARRANT REPRESENTED BY THIS CERTIFICATE AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS AND NEITHER SUCH
SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR (2) THE
COMPANY RECEIVES AN OPINION OF COUNSEL TO THE HOLDER OF SUCH SECURITIES, WHICH COUNSEL AND OPINION ARE REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR TRANSFERRED IN THE MANNER CONTEMPLATED
WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR APPLICABLE STATE SECURITIES LAWS. 
 THE TRANSFER OF THIS WARRANT IS

 RESTRICTED AS DESCRIBED HEREIN. 
 ACCENTIA BIOPHARMACEUTICALS, INC. 
 Warrant for the Purchase up to XXXXX
(                ) Shares 
 of Common Stock, par value
$ 0.001 per share 
 THIS WARRANT EXPIRES ON JUNE     , 2011 
                  Shares of Common Stock @
$             per share 
 This Warrant certifies that, for value
received,                     , with an address at
                             (including any transferee, the “Holder”), is entitled to
subscribe for and purchase from ACCENTIA BIOPHARMACEUTICALS, INC., a Florida corporation (the “Company”), upon the terms and conditions set forth herein, up to an aggregate of
             shares of the Company Common Stock, par value $0.001 per share (“Common Stock”), at a price (the “Exercise Price”) equal to
$             per share, on the following vesting schedule: 
 Rights to
purchase all shares pursuant to this Warrant shall vest immediately upon Grant. 
 All rights to purchase shares pursuant to this Warrant
must be exercised before 5:00 P.M. on June     , 2011, New York time (the “Exercise Period”), unless such Exercise Period is extended as set forth hereinafter. As used herein the term “this Warrant”
shall mean and include this Warrant and any Warrant or Warrants hereafter issued as a consequence of the exercise or transfer of this Warrant in whole or in part. 

 The number of shares of Common Stock issuable upon exercise of the Warrants (the “Warrant
Shares”) and the Exercise Price may be adjusted from time to time as hereinafter set forth. 
 1. This Warrant may be exercised during
the Exercise Period, as to the whole or any lesser number of whole Warrant Shares, by the surrender of this Warrant (with the “Election to Exercise” attached hereto, duly executed) to the Company at its office at 324 Hyde Park
Avenue, Suite 350, Tampa, FL 33606 or at such other place as is designated in writing by the Company, together with cash or a certified or bank cashiers check payable to the order of the Company in an amount equal to the Exercise Price multiplied by
the number of Warrant Shares for which this Warrant is being exercised. Each Warrant not exercised prior to 5:00 p.m. on June     , 2011 New York time shall become null and void and all rights thereunder shall cease
as of such time. 
 2. The Holder shall be deemed to be the holder of record of the Warrant Shares as soon as the Company receives the
Warrant, the “Election to Exercise” and the aggregate Exercise Price for the Warrant Shares in accordance with Section 1; provided, however, that if the date of such receipt is a date upon which the transfer books of the Company are
closed, the Holder shall be deemed to be the record holder on the next succeeding business day on which such books are open. As soon as practicable after each such exercise of this Warrant, the Company shall issue and cause to be delivered to the
Holder a certificate or certificates for the Warrant Shares issuable upon such exercise, registered in the name of the Holder or its designee. If this Warrant is exercised in part only, the Company shall, upon surrender of this Warrant for
cancellation, execute and deliver a new Warrant evidencing the right of the Holder to purchase the remaining unexercised balance of the Warrant Shares (or portions thereof) subject to purchase hereunder. 
 3.(a) Any Warrants issued upon the transfer or exercise in part of this Warrant shall be numbered and shall be registered in a Warrant Register as they
are issued. The Company shall be entitled to treat the registered holder of any Warrant on the Warrant Register as the owner in fact thereof for all purposes and shall not be bound to recognize any equitable or other claim to or interest in such
warrant on the part of any other person, and shall not be liable for any registration or transfer of Warrants which are registered or to be registered in the name of a fiduciary or the nominee of a fiduciary unless made with the actual knowledge
that a fiduciary or nominee is committing a breach of trust in requesting such registration or transfer, or with the knowledge of such facts that its participation therein amounts to bad faith. This Warrant shall be transferable only on the books of
the Company upon delivery thereof duly endorsed by the Holder or by his duly authorized attorney or representative, or accompanied by proper evidence of succession, assignment, or authority to transfer. In all cases of transfer by an attorney,
executor, administrator, guardian, or other legal representative, duly authenticated evidence of his or its authority shall be produced. Upon any registration of the transfer of this Warrant, the Company shall cause to be delivered a new Warrant or
Warrants to the person entitled thereto. This Warrant may be exchanged, at the option of the Holder thereof, for another Warrant, or other Warrants of different denominations, of like tenor and representing in the aggregate the right to purchase a
like number of Warrant Shares (or portions thereof), upon surrender to the Company or its duly authorized agent. Notwithstanding the foregoing, the Company shall have no obligation to cause Warrants to be transferred on its books to any person if,
in the opinion of counsel to the Company, such transfer does not comply with the provisions of the Securities Act of 1933, as amended (the “Act”), and the rules and regulations thereunder. 
  

 2 

 (b) The Holder acknowledges that he has been advised by the Company that neither this Warrant nor the
Warrant Shares have been registered under the Act, that this Warrant is being or has been issued and the Warrant Shares may be issued on the basis of the statutory exemption provided by Section 4(2) of the Act or Regulation D promulgated
thereunder, or both, relating to transactions by an issuer not involving any public offering, and that the Company’s reliance thereon is based in part upon the representations to the Company made by the original Holder. The Holder acknowledges
that he is familiar with the nature of the limitations imposed by the Act and the rules and regulations thereunder on the transfer of securities. In particular, the Holder agrees that no sale, assignment or transfer of this Warrant or the Warrant
Shares issuable upon exercise hereof shall be valid or effective, and the Company shall not be required to give any effect to any such sale, assignment or transfer, unless (i) the sale, assignment or transfer of this Warrant or such Warrant
Shares is registered under the Act, it being understood that neither this Warrant nor such Warrant Shares are currently registered for sale and that the Company has no obligation or intention to so register this Warrant or such Warrant Shares except
as specifically provided herein, or (ii) this Warrant or such Warrant Shares are sold, assigned or transferred in accordance with all the requirements and limitations of Rule 144 under the Act, it being understood that Rule 144 is not available
at the time of the original issuance of this Warrant for the sale of this Warrant or such Warrant Shares and that there can be no assurance that Rule 144 sales will be available at any subsequent time, or (iii) such sale, assignment, or
transfer is otherwise exempt from registration under the Act. 
 (c) The Holder represents that he/she is an “Accredited Investor”
as defined in the Act. 
 (d) Piggyback Registration Rights. In the event that the Company plans to file a registration statement with
the U. S. Securities and Exchange Commission covering shares of common stock of the Company (“Registration Statement”), the Company shall provide written notice to Holder and Holder shall have 30 days to require in writing that all shares
of common stock underlying the Warrant, to the extent vested, be covered in the Registration Statement. Notwithstanding the foregoing, the Company shall have full discretion to determine not to include the shares underlying the warrant in any
registration statement if the Company reasonably determines that such registration may adversely effect the registration statement, the offering described in the registration statement or otherwise adversely affect the Company. 
 4. The Company shall at all times reserve and keep available out of its authorized and unissued Common Stock solely for the purpose of providing for the
exercise of the rights to purchase Warrant Shares granted pursuant to the outstanding Warrants, such number of shares of Common Stock as shall, from time to time, be required therefor. The Company covenants that the Warrant Shares, upon receipt by
the Company of the full Exercise Price therefor, shall be validly issued, fully paid, nonassessable, and free of preemptive rights. 
  

 3 

 5. (a) In case of any consolidation with or merger of the Company with or into another corporation
(other than a merger or consolidation in which the Company is the surviving or continuing corporation), or in case of any sale, lease, or conveyance to another corporation of the property and assets of any nature of the Company as an entirety or
substantially as an entirety, such successor, leasing, or purchasing corporation, as the case may be, the Company shall (i) execute with the Holder an agreement providing that the Holder shall have the right thereafter to receive upon exercise
of this Warrant solely the kind and amount of shares of stock and other securities, property, cash, or any combination thereof receivable upon such consolidation, merger, sale, lease, or conveyance by a holder of the number of shares of Common Stock
for which this Warrant might have been exercised immediately prior to such consolidation, merger, sale, lease, or conveyance, and (ii) make effective provision in its certificate of incorporation or otherwise, if necessary, to effect such
agreement. Such agreement shall provide for adjustments which shall be as nearly equivalent as practicable to the adjustments in Section 5. 
 (b) In case of any reclassification or change of the shares of Common Stock issuable upon exercise of this Warrant (other than a change in par value or from no par value to a specified par value, or as a result of a subdivision or
combination, but including any change in the shares into two or more classes or series of shares), or in case of any consolidation or merger of another corporation into the Company in which the Company is the continuing corporation and in which
there is a reclassification or change (including a change to the right to receive cash or other property) of the shares of Common Stock (other than a change in par value, or from no par value to a specified par value, or as a result of a subdivision
or combination, but including any change in the shares into two or more classes or series of shares), the Holder shall have the right thereafter to receive upon exercise of this Warrant solely the kind and amount of shares of stock and other
securities, property, cash, or any combination thereof receivable upon such reclassification, change, consolidation, or merger by a holder of the number of shares of Common Stock for which this Warrant might have been exercised immediately prior to
such reclassification, change, consolidation, or merger. 
 (c) The above provisions of this Section 6 shall similarly apply to
successive reclassifications and changes of shares of Common Stock and to successive consolidations, mergers, sales, leases, or conveyances. 
 (d) This Warrant is fully assignable, as to all or any portion of the rights hereunder, at the discretion of the Holder. The Company will issue the necessary Warrants to give effect to any such assignment upon receipt of a
properly-completed Assignment in the form attached to this Warrant, signed by the Holder. 
 6. The issuance of any shares or other
securities upon the exercise of this Warrant, and the delivery of certificates or other instruments representing such shares or other securities, shall be made without charge to the Holder for any tax or other charge in respect of such issuance. The
Company shall not, however, be required to pay any tax which may be payable in respect of any transfer or delivery of this Warrant to a person other than, or the issuance and delivery of any certificate in a name other than that of the registered
Holder and the Company shall not be required to issue or deliver any such certificate unless and until the person or persons requesting the issue thereof shall have paid to the Company the amount of such tax or shall have established to the
satisfaction of the Company that such tax has been paid. 
  

 4 

 7. Until such time as an effective Registration Statement covering the Warrant Shares is in place, the
Warrant Shares issued upon exercise of the Warrants shall be subject to a stop transfer order and the certificate or certificates evidencing such warrant Shares shall bear the following legend: 
 “THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE
SECURITIES LAWS AND NEITHER SUCH SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE ACT AND ANY APPLICABLE STATE
SECURITIES LAWS, OR (2) THE COMPANY RECEIVES AN OPINION OF COUNSEL TO THE HOLDER OF SUCH SECURITIES, WHICH COUNSEL AND OPINION ARE REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR
TRANSFERRED IN THE MANNER CONTEMPLATED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR APPLICABLE STATE SECURITIES LAWS.” 
 In addition, any Warrants issued upon transfer or any new Warrants issued shall bear a similar legend. 
 8. Upon receipt of
evidence satisfactory to the Company of the loss, theft, destruction, or mutilation of any Warrant (and upon surrender of any Warrant if mutilated) , including an affidavit of the Holder thereof that this Warrant has been lost, stolen, destroyed or
mutilated, together with an indemnity against any claim that may be made against the Company on account of such lost, stolen, destroyed or mutilated Warrant, and upon reimbursement of the Company’s reasonable incidental expenses, the Company
shall execute and deliver to the Holder thereof a new Warrant of like date, tenor, and denomination. 
 9. The Holder of any Warrant shall
not have, solely on account of such status, any rights of a stockholder of the Company, either at law or in equity, or to any notice of meetings of stockholders or of any other proceedings of the Company, except as provided in this warrant.

  

 5 

 10. This Warrant shall be construed in accordance with the laws of the State of Florida applicable to
contracts made and performed within such State, without regard to principles governing conflicts of law. 
 11. The Company irrevocably
consents to the jurisdiction of the courts of the State of Florida and of any federal court located in such State in connection with any action or proceeding arising out of or relating to this Warrant, any document or instrument delivered pursuant
to, in connection with or simultaneously with this Warrant, or a breach of this Warrant or any such document or instrument. 
 12. Any notice
or other communication required or permitted to be given hereunder shall be in writing and shall be mailed by certified mail, return receipt requested, or by Federal Express, Express Mail or similar overnight delivery or courier service or delivered
(in person or by telecopy, telex or similar telecommunications equipment) against receipt to the party to whom it is to be given, (i) if to the Company, at 324 Hyde Park Avenue, Suite 350, Tampa FL 33606, Attention: CFO, (ii) if to the
Holder, at its address set forth on the first page hereof, or (iii) in either case, to such other address as the party shall have furnished in writing in accordance with the provisions of this Section 13. Notice to the estate of any party
shall be sufficient if addressed to the party as provided in this Section 13. Any notice or other communication given by certified mail shall be deemed given at the time of certification thereof, except for a notice changing a party’s
address which shall be deemed given at the time of receipt thereof. Any notice given by other means permitted by this Section 13 shall be deemed given at the time of receipt thereof. 
 13. This Warrant may be amended only by a written instrument executed by the Company and the Holder hereof. Any amendment shall be endorsed upon this
Warrant, and all future Holders shall be bound thereby. 
 Dated:
                    , 2007 
  

			
	ACCENTIA BIOPHARMACEUTICALS, INC.
		
	By:	 	  

	Name:	 	  

	Title:	 	  

  

 6 

 FORM OF ASSIGNMENT 
 (To be executed by the registered holder if such holder desires to transfer all or any portion of the rights in and to the attached Warrant.) 
 FOR VALUE RECEIVED,
                             hereby sells, assigns, and transfers unto
                             a Warrant to purchase
                             shares of Common Stock, par value $0.001 per share, of ACCENTIA
BIOPHARMACEUTICALS, INC. (the “Company”), together with all right, title, and interest therein, and does hereby irrevocably constitute and appoint
                             attorney to transfer such Warrant on the books of the Company, with full
power of substitution. 
 Dated:
                         
  

			
	 Signature
	 	  

	
	  

	 Signature Guarantee

 NOTICE 
 The signature on the foregoing Assignment must correspond to the name as written upon the face of this Warrant in every particular, without alteration or enlargement or any change whatsoever. 
  

 7 

	To:	ACCENTIA BIOPHARMACEUTICALS, INC. 

 324 S. Hyde Park
Avenue, Suite 350 
 Tampa, FL 33606 
 ELECTION TO EXERCISE 
 The undersigned hereby exercises his or its rights to purchase
                             Warrant Shares covered by the within Warrant and tenders payment herewith
in the amount of $                     in accordance with the terms thereof, and requests that certificates for such securities be issued in
the name of, and delivered to: 
  

  

  

 (Print
Name, Address and Social Security or Tax Identification Number) 
 and, if such number of Warrant shares shall not be all the Warrant Shares covered by the
within Warrant, that a new Warrant for the balance of the Warrant Shares covered by the within Warrant be registered in the name of, and delivered to, the undersigned at the address stated below. 
  

  

  

 (Print Name, Address and Social Security or Tax
Identification Number) 
 and, if such number of Warrant Shares shall not be all the Warrant Shares covered by the within Warrant, that a new Warrant for the
balance of the Warrant Shares covered by the within Warrant be registered in the name of, and delivered to, the undersigned at the address stated below. 
 Dated:                         
 Name:                                     
    (Print) 
 Address:
                                        
                                        
                                 
  

	
	  

	 (Signature)

	
	  

	 (Signature Guarantee)

	
	  

	 (Signature Guarantee)

  

 8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00125-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00125-of-00352.parquet"}]]